Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px
Document › Details

Bayer AG. (9/2/14). "Press Release: Bayer Closes on Divestiture of Interventional Device Business to Boston Scientific". Leverkusen.

Organisations Organisation Bayer HealthCare (Group)
  Group Bayer (Group)
  Organisation 2 Boston Scientific Corporation (NYSE: BSX)
  Group Boston Scientific (Group)
Products Product Jetstream™ Atherectomy System
  Product 2 catheter
Index term Index term Bayer–Boston Scientific: investment, 201405–201409 acquisition $415m of interventional device business by Boston Scientific

Bayer HealthCare closed on the divestiture of its Interventional device business to Boston Scientific. The total consideration for the transaction, including fees for transitional services, is USD 415 million (about EUR 300 million). With this sale, Bayer HealthCare's Medical Care division can concentrate on innovation and growth in Radiology and Diabetes Care, where the business already has a strong presence.

The sale includes the AngioJet™ (thrombectomy) and Jetstream™ (atherectomy) systems, and the Fetch™2 Aspiration Catheter used in cardiology, radiology and peripheral vascular procedures. Bayer's Interventional business accounted for approximately USD 120 million in sales in 2013.

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 18.9 billion (2013), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 56,000 employees (Dec 31, 2013) and is represented in more than 100 countries. More information is available at

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Record changed: 2017-04-02


Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

More documents for Bayer (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top